About the API
Cinacalcet hydrochloride is a calcimimetic agent, meaning that it mimics the action of calcium. It is used to treat elevated calcium levels in the blood in the following disorders: secondary hyperparathyroidism (HPT) in patients with chronic kidney disease on dialysis; hypercalcemia in patients with parathyroid carcinoma; and severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.
In these disorders, high levels of parathyroid hormone (PTH) are released from the parathyroid glands, which are located in the neck behind the thyroid gland. Parathyroid glands control the level of calcium in the blood through release of this hormone, which causes calcium to leave the bone into the blood stream. Hyperactivation of parathyroid glands causes increased calcium levels in the blood and progressive depletion of calcium from the bones.
Cinacalcet was launched in Australia, Canada, the EU, the UK, the US, and New Zealand as a treatment for hypercalcaemia in patients with parathyroid carcinoma. Cinacalcet is marketed as Mimpara in Europe and as Sensipar elsewhere for this indication. Cinacalcet (Regpara) was granted orphan drug designation for this indication in Japan (launched in 2015).